Clinical trials: Pelcitoclax
Neuroendocrine Tumors
A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors
APG-1252 is a highly potent Bcl-2 family protein inhibitor, a promising drug candidate which shown high binding affinities to Bcl-2, Bcl-xL and Bcl-w.
- Trial name
- NCT04893759
- Testing
- Pelcitoclax
- Where
- 3 sites in China
- Volunteers
- 2 people
- Sponsor
- Ascentage Pharma Group Inc.
Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
This phase I trial tests the safety, side effects, and best dose of combination therapy with pelcitoclax (APG-1252) and cobimetinib in treating patients with ovarian and endometrial cancers that have come back after a period of…
- Conditions
- Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Platinum-Resistant Ovarian Carcinoma
- Trial name
- NCT05691504
- Testing
- Biopsy Procedure, Biospecimen Collection, Cobimetinib
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Phase I, FLAG Chemotherapy
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
To find safe and effective doses of lisaftoclax and pelcitoclax in combination with FLAG chemotherapy in patients with relapsed/refractory T-ALL.
- Conditions
- Phase I, FLAG Chemotherapy, Lisaftoclax, Pelcitoclax
- Trial name
- NCT07428486
- Testing
- Fludarabine, Cytarabine, G-CSF
- Sponsor
- M.D. Anderson Cancer Center